Yasodha Natkunam
0000-0002-9816-1018
Stanford Medicine
185 papers found
Refreshing results…
Nanoscale analysis of changes in signaling proteins in patients treated with single agent atorvastatin for low-grade or refractory NHL
Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin:
Lack of Utility of CD20 Immunohistochemistry in Staging Bone Marrow Biopsies for Diffuse Large B-cell Lymphoma
The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms and Selected Other Entities
Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes: integration of tumor and microenvironment contributions
Neither CD68+ Nor CD163+ Macrophages Are Associated with Decreased Survival in Follicular Lymphoma
Lymphoma-Expressed VEGF-a, VEGFR-1, VEGFR-2, and Microvessel Density Are Not Predictive of Overall Survival in Follicular Lymphoma
PTP1B is a negative regulator of interleukin 4–induced STAT6 signaling
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
Biological and clinical effects of single agent treatment with atorvastatin in patients with non-Hodgkin’s lymphoma
Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960–2003
Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis
Expression of HGAL in primary cutaneous large B-cell lymphomas: Evidence for germinal center derivation of primary cutaneous follicular lymphoma
LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab
LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study.
LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.
Paraffin-Based 6-Gene Model Predicts Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
Survival in Follicular Lymphoma: The Stanford Experience, 1960–2003.
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy
Bone Marrow Diagnosis
Missing publications? Search for publications with a matching author name.